MCRB · Company research
Seres Therapeutics, Inc. (MCRB): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
20records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026 | Seres Therapeutics announced preclinical data for SER-428, an investigational live biotherapeutic designed to reduce bloodstream infections in critically ill patients. The novel oral liquid formulation showed up to 1,000-fold reduction of pathogenic bacteria in preclinical models and builds on positive results from SER-155. The company is designing a Phase 1b trial in collaboration with Columbia University, with further development pending funding. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bullish | 1 | 1 |
| Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026 | Seres Therapeutics announced preclinical data for SER-428, an investigational live biotherapeutic designed to reduce bloodstream infections in critically ill patients. The novel oral liquid formulation showed up to 1,000-fold reduction of pathogenic bacteria in preclinical models and builds on positive results from SER-155. The company is designing a Phase 1b trial in collaboration with Columbia University, with further development pending funding. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bullish | 1 | 1 |
| A liquid experimental treatment reduced two bacteria up to 1,000-fold in preclinical tests. - Stock Titan | A liquid experimental treatment reduced two bacteria up to 1,000-fold in preclinical tests. Stock Titan | View source ↗ | Stock Titan | Oct 15, 2026 | neutral | 0 | 0.6 |
| MCRB Oct 2026 5.000 put (MCRB261016P00005000) Interactive Stock Chart - Yahoo Finance - Yahoo! Finance Canada | MCRB Oct 2026 5.000 put (MCRB261016P00005000) Interactive Stock Chart - Yahoo Finance Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 4, 2026 | neutral | 0 | 0.6 |
| Seres Therapeutics (MCRB) Ticks Up 0.34% to $2.94 as $3.09 Resistance Comes Into Focus - Money Flow - siam.in | Seres Therapeutics (MCRB) Ticks Up 0.34% to $2.94 as $3.09 Resistance Comes Into Focus - Money Flow siam.in | View source ↗ | siam.in | Oct 2, 2026 | neutral | 0 | 0.6 |
| Seres Therapeutics (MCRB) Edges Up to $4.02 as Buyers Defend Near-Term Support - Leading Diagonal - https://www.dars.gov.et/ | Seres Therapeutics (MCRB) Edges Up to $4.02 as Buyers Defend Near-Term Support - Leading Diagonal https://www.dars.gov.et/ | View source ↗ | https://www.dars.gov.et/ | Sep 21, 2026 | neutral | 0 | 0.6 |
| Two new hires get options on 4,200 Seres shares - Stock Titan | Two new hires get options on 4,200 Seres shares Stock Titan | View source ↗ | Stock Titan | Sep 8, 2026 | neutral | 0 | 0.6 |
| Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference - Stock Titan | Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference Stock Titan | View source ↗ | Stock Titan | Sep 1, 2026 | neutral | 0 | 0.6 |
| Seres Therapeutics (MCRB) Advances 3.23% to $5.11 as Biotech Stock Holds Key Support Zone - Call Wall - siam.in | Seres Therapeutics (MCRB) Advances 3.23% to $5.11 as Biotech Stock Holds Key Support Zone - Call Wall siam.in | View source ↗ | siam.in | Aug 29, 2026 | neutral | 0 | 0.6 |
| Seres Therapeutics, Inc. SEC Filing (Aug 24, 2026) - Stock Titan | Seres Therapeutics, Inc. SEC Filing (Aug 24, 2026) Stock Titan | View source ↗ | Stock Titan | Aug 24, 2026 | neutral | 0 | 0.6 |
| Seres Therapeutics, Inc. Revenue Breakdown – NASDAQ:MCRB - TradingView | Seres Therapeutics, Inc. Revenue Breakdown – NASDAQ:MCRB TradingView | View source ↗ | TradingView | Aug 16, 2026 | neutral | 0 | 0.6 |
| Why Is Seres Therapeutics Stock Falling Today? - Seres Therapeutics (NASDAQ:MCRB) - Benzinga | Why Is Seres Therapeutics Stock Falling Today? - Seres Therapeutics (NASDAQ:MCRB) Benzinga | View source ↗ | Benzinga | Jul 8, 2026 | neutral | 0 | 0.6 |
| Here's Why We're A Bit Worried About Seres Therapeutics' (NASDAQ:MCRB) Cash Burn Situation - Simply Wall Street | Here's Why We're A Bit Worried About Seres Therapeutics' (NASDAQ:MCRB) Cash Burn Situation Simply Wall Street | View source ↗ | Simply Wall Street | Jun 13, 2026 | neutral | 0 | 0.6 |
| We're A Little Worried About Seres Therapeutics' (NASDAQ:MCRB) Cash Burn Rate - Yahoo Finance | We're A Little Worried About Seres Therapeutics' (NASDAQ:MCRB) Cash Burn Rate Yahoo Finance | View source ↗ | Yahoo Finance | Jun 13, 2026 | neutral | 0 | 0.6 |
| Seres Therapeutics (MCRB) Slips 3.4%, Testing Key Support at $6.95 - Gamma Flip Level - po-news-eg.net | Seres Therapeutics (MCRB) Slips 3.4%, Testing Key Support at $6.95 - Gamma Flip Level po-news-eg.net | View source ↗ | po-news-eg.net | May 31, 2026 | neutral | 0 | 0.6 |
| MCRB Stock Declines As Seres Therapeutics Pauses SER-155 Phase 2 Study And Shrinks Headcount By 30% - Stocktwits | MCRB Stock Declines As Seres Therapeutics Pauses SER-155 Phase 2 Study And Shrinks Headcount By 30% Stocktwits | View source ↗ | Stocktwits | Feb 12, 2026 | neutral | 0 | 0.6 |
| Seres Therapeutics: Strong SER-155 Data, But Dilution Risk Now Warrants A 'Hold' - Seeking Alpha | Seres Therapeutics: Strong SER-155 Data, But Dilution Risk Now Warrants A 'Hold' Seeking Alpha | View source ↗ | Seeking Alpha | Feb 6, 2026 | neutral | 0 | 0.6 |
| Should I buy Seres Therapeutics (MCRB) - Zacks Investment Research | Should I buy Seres Therapeutics (MCRB) Zacks Investment Research | View source ↗ | Zacks Investment Research | Dec 29, 2025 | neutral | 0 | 0.6 |
| Seres Therapeutics Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis | Seres Therapeutics Stock Drop Looks Sharp, But How Deep Can It Go? Trefis | View source ↗ | Trefis | Nov 30, 2025 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Feb 12, 2024 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.